Sonnet BioTherapeutics : Announces Updated Clinical Data for

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target



...

Related Keywords

United States , Pankaj Mohan , Jack Yauch , Robert Wenham , Richard Kenney , Nasdaq , Sonnet Biotherapeutics Holdings Inc , Exchange Commission , Solebury Strategic Communications , Genentech , Oncology At Moffitt Cancer Center , Company Or Sonnet , Roche Group , Securities Exchange , Fully Human Albumin Binding , Secreted Protein Acidic , Safety Review Committees , Chief Medical , Response Evaluation Criteria , Solid Tumors , Moffitt Cancer Center , Lead Principal Investigator , Sonnet Founder , Chief Executive , Secreted Protein , Programed Death Ligand , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act ,